Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Gynecologic Oncology

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2004.03.023PMID 15196867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum

  2004cited by this paper
• Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.

  2003cited by this paper
• Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Optimizing primary chemotherapy in ovarian cancer.

  2003cited by this paper
• Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.

  2000cited by this paper
• Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

  2000cited by this paper
• Second-line treatment of ovarian cancer.

  2000cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper

• 1,3,5-Tricaffeoylquinic Acid from Ipomoea batatas Vines Induced Ovarian Cancer Cell Apoptosis and Inhibited Endothelial Tube Formation

  2025cites this paper
• New trends in diagnosing and treating ovarian cancer using nanotechnology

  2023cites this paper
• Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs

  2023cites this paper
• Insight into RNA-based therapies for ovarian cancer.

  2023cites this paper
• Platinum-Pemetrexed Chemotherapy for Recurrent Ovarian Cancer (ROC): A Single Center Experience

  2021cites this paper
• Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.

  2021cites this paper
• Recombinant Chinese Hu191 measles virus exhibits a significant antitumor activity against nephroblastoma mediated by immunogenic form of apoptosis.

  2021cites this paper
• Self-Amplifying RNA Viruses as RNA Vaccines

  2020cites this paper
• Pharmaceutical Management of Ovarian Cancer: Current Status

  2019cites this paper
• Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis

  2019cites this paper
• Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model

  2018cites this paper
• Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

  2017cites this paper
• PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells.

  2016cites this paper
• Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

  2015cites this paper
• ResearchCurcumin induces chemo / radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth

  2015cites this paper
• Advances in the design and development of oncolytic measles viruses

  2015cites this paper
• Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

  2015cites this paper
• Genetic Engineering of Oncolytic Viruses for Cancer Therapy

  2015cites this paper
• Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells

  2014cites this paper
• Curcumin and lung cancer—a review

  2014cites this paper
• Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma

  2014cites this paper
• Prognostic Impact of Human Leukocyte Antigen Class I Expression and Association of Platinum Resistance with Immunologic Profiles in Epithelial Ovarian Cancer

  2014cites this paper
• Oncolytic virus therapy for cancer: the first wave of translational clinical trials.

  2013cites this paper
• Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

  2013cites this paper
• Oncolytic measles virus strains : biologic characteristics , cytopathic activity and cancer selectivity

  2013cites this paper
• Oncolytic measles virus strains as novel anticancer agents

  2013cites this paper
• Platinum-resistant ovarian cancer: Prematurely stopped phase II Austrian AGO chemotherapy studies

  2012cites this paper
• Attenuated oncolytic measles virus strains as cancer therapeutics.

  2012cites this paper
• A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

  2012cites this paper
• Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

  2012cites this paper
• Pharmaceutical Management of Ovarian Cancer

  2012cites this paper
• Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer.

  2011cites this paper
• Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

  2010cites this paper
• Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience

  2010cites this paper
• A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.

  2010cites this paper
• Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges

  2010cites this paper
• The Clinical Impact of Computed Tomography Immediately Following Primary Chemotherapy in Patients With Epithelial Ovarian Cancer

  2010cites this paper
• Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth

  2010cites this paper
• Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

  2009cites this paper
• Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy

  2009cites this paper
• 再発・再燃卵巣癌に対する胸腔内・腹腔内化学療法およびホルモン療法 ―症例報告―

  2009cites this paper
• Activated p38-MAPK and gemcitabine sensitivity in recurrent ovarian cancer.

  2008cites this paper
• An Example of Ovarian Cancer as a ‘Chronic Disease Process' – 11-Year Survival with Multiple Treatments for Recurrent and Progressive Disease

  2008cites this paper
• Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer

  2008cites this paper
• Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice

  2007cites this paper
• Aktuelle Aspekte der Therapie des platinresistenten Ovarialkarzinoms

  2007cites this paper
• Long-term semi-permanent catheter use for the palliation of malignant ascites.

  2006cites this paper
• Another Example of the Highly Variable Clinical Course of Recurrent/Resistant/Persistent Ovarian Cancer

  2006cites this paper
• Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.

  2006cites this paper
• Ovarian cancer: a focus on management of recurrent disease

  2006cites this paper
• Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

  2006cites this paper
• Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.

  2006cites this paper
• Traitement médical des rechutes (récidives) précoces

  2006cites this paper
• The current treatment of recurrent ovarian cancer

  2006cites this paper
• Palliative chemotherapy "near the end-of-life" in ovarian cancer: not necessarily "aggressive cure-oriented therapy".

  2006cites this paper
• Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.

  2005cites this paper
• Multi‐institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S‐transferase P1‐1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

  2005cites this paper
• Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

  2005cites this paper
• Survival following the documentation of platinum and taxane resistance in ovarian cancer.

  2004cites this paper
• PBOV 1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells

  year unknowncites this paper